Author

Norman G. Nagl

Observed names: N. Nagl, Norman G Nagl, Norman Nagl, Norman G. NAGL

Observed institutions: Actinium Pharmaceuticals (United States), Eisai (United States), Eisai (Japan), Temple University

OpenAlex ID: A5014559674

Distinct mammalian SWI/SNF chromatin remodeling complexes with opposing roles in cell‐cycle control

2007 · Norman G Nagl, Xiaomei Wang, et al. · The EMBO Journal · 236

Two related ARID family proteins are alternative subunits of human SWI/SNF complexes

2004 · Xiaomei WANG, Norman G. NAGL, et al. · Biochemical Journal · 178

The p270 (ARID1A/SMARCF1) Subunit of Mammalian SWI/SNF-Related Complexes Is Essential for Normal Cell Cycle Arrest

2005 · Norman G. Nagl, Antonia Patsialou, et al. · Cancer Research · 145

The c-myc Gene Is a Direct Target of Mammalian SWI/SNF–Related Complexes during Differentiation-Associated Cell Cycle Arrest

2006 · Norman G. Nagl, Daniel R. Zweitzig, et al. · Cancer Research · 120

Antagonistic Roles for BRM and BRG1 SWI/SNF Complexes in Differentiation

2009 · Stephen Flowers, Norman G. Nagl, et al. · Journal of Biological Chemistry · 105

Expression of p270 (ARID1A), a component of human SWI/SNF complexes, in human tumors

2004 · Xiaomei Wang, Norman G. Nagl, et al. · International Journal of Cancer · 93

Expression of Genes Encoding Chromatin Regulatory Factors in Developing Rhesus Monkey Oocytes and Preimplantation Stage Embryos: Possible Roles in Genome Activation1

2004 · Ping Zheng, Bela Patel, et al. · Biology of Reproduction · 42

Outcomes Associated with 5-HT3-RA Therapy Selection in Patients with Chemotherapy-Induced Nausea and Vomiting: A Retrospective Claims Analysis.

2014 · Claudio Faria, Xuan Li, et al. · PubMed · 10

Impact on patients’ daily life activities of NEPA, the oral fixed-dose combination of netupitant, a new NK1 receptor antagonist (RA), and palonosetron (PALO) plus dexamethasone (DEX) versus PALO plus DEX for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic chemotherapy (MEC).

2013 · Matti S. Aapro, Giorgia Rossi, et al. · Journal of Clinical Oncology · 5

131I-Apamistamab Improves Outcomes in Patients 65 Years and Older with Relapsed or Refractory AML

2024 · Rajneesh Nath, Stuart Seropian, et al. · Transplantation and Cellular Therapy · 3

High-Dose Targeted Radiation with 131I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

2023 · Mark R. Litzow, George Chen, et al. · Blood · 2

131I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant for Patients with TP53 Mutated R/R AML Results in Significantly Improved Outcomes

2024 · James Foran, Boglarka Gyurkocza, et al. · Transplantation and Cellular Therapy · 1

Targeted Myeloablative Radiation Using 131I-Apamistamab Prior to Allogeneic Hematopoietic Cell Transplant for Patients with R/R AML Results in Robust Engraftment

2024 · Hannah Choe, Dr. Rajneesh Nath, et al. · Transplantation and Cellular Therapy

Charges Associated With Chemotherapy Induced Nausea And Vomiting In Cancer Patients Initiating And Maintaining Therapy With A 5-Ht3-Ra Throughout Chemotherapy Cycles

2013 · C. Faria, N. Nagl, et al. · Value in Health

Works count: 14

Citation count: 940

H-index: 8

I10-index: 8